Thus, in addition to the approved therapies that enhance the sGC‐cGMP pathway, targeting the uncoupling of eNOS may be beneficial in the treatment of PAH (Hansen et al., 2016). The gene discussed is SGCB; the disease is pulmonary arterial hypertension.